Trial intelligence / Profile preview

Fluarix immunogenicity and safety in adolescents previously vaccinated with Pandemrix

2010-020331-39Phase 4Completed

Sponsor
GSK
Start
Jul 2010
Modality
Vaccines & Immunotherapeutics
Countries
1
01

Overview

Phase 4, randomised, open-label trial of Fluarix in influenza, sponsored by GSK. Primary endpoints: Humoral immune response against H1N1 strain at Day 28 and Safety and reactogenicity after Fluarix vaccination. Started Jul 2010; status: completed.

02

Drugs

Fluarix
03

Conditions

influenza

Beyond the preview

Go deeper on 2010-020331-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-020331-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call